PLEXIFORM NEUROFIBROMAS TREATMENT MARKET ANALYSIS

Plexiform Neurofibromas Treatment Market, by Drug Class (Selumetinib, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticonvulsants, Others (Tricyclic Antidepressants, etc.)), by Patient Population (Pediatric, Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI5430
Pages :415
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Plexiform Neurofibromas Treatment Market: Key Developments

Increasing adoption of inorganic strategies such as product approval by regulatory authorities such as European Commission is expected to drive the gloal plexiform neurofibromas treatment over the forecast period. For instance, in June 2021, AstraZeneca Plc., a pharmaceutical company, announced that the Koselugo (selumetinib) had been granted conditional approval in the European Union for the treatment of symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1 aged 3 years and above. The approval by the European Commission was based on positive results from the SPRINT Stratum 1 Phase II trial sponsored by the National Institute of Health's National Cancer Institute Cancer Therapy Evaluation Program. The SPRINT Phase II trial indicated that Koselugo (selumetinib) reduced the tumor volume in children, reducing the pain.